MacroGenics, Inc. (MGNX) P/E Ratio History
Historical price-to-earnings valuation from 2013 to 2023
Loading P/E history...
MGNX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, MacroGenics, Inc. (MGNX) trades at a price-to-earnings ratio of -2.6x, with a stock price of $3.01 and trailing twelve-month earnings per share of $-1.18.
The current P/E is 100% below its 5-year average of 844.8x. Over the past five years, MGNX's P/E has ranged from a low of 5.9x to a high of 2016.7x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, MGNX trades at a 112% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, MGNX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MGNX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MGNX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $363B | 86.5 | - | -1% | |
| $75B | 17.4Lowest | 2.75Best | +8% | |
| $179B | 23.3 | 7.91 | +88%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MGNX Historical P/E Data (2013–2023)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $4.66 | $0.79 | 5.9x | -99% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $5.35 | $0.11 | 48.6x | -94% |
| FY2015 Q1 | $31.37 | $0.19 | 165.1x | -80% | |
| FY2014 Q1 | Mon Mar 31 2014 00:00:00 GM | $27.83 | $0.01 | 2016.7x | +139% |
| FY2013 Q4 | $27.43 | $0.01 | 1987.7x | +135% |
Average P/E for displayed period: 844.8x
See MGNX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MGNX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MGNX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMGNX — Frequently Asked Questions
Quick answers to the most common questions about buying MGNX stock.
Is MGNX stock overvalued or undervalued?
MGNX trades at -2.6x P/E, below its 5-year average of 844.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MGNX's valuation compare to peers?
MacroGenics, Inc. P/E of -2.6x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is MGNX's PEG ratio?
MGNX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2023.